Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corixa [CRXA] - cancer vaccines -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (43)	1/27/2001 8:43:17 PM
From: hmpa	Read Replies (1) \| Respond to of 222

What looks like the tremendous increase in short interest from 12/00 to 01/01 (by about 1.9 mln shares) seems to be a transfer of CLTR short position (2.8 mln) minus some. So, currently a combination of the pipelines of the two has a market cap smaller than any one of them at least at some time in 2000, plus some huge short interest. Make your choice from the three explanations: (a)CRXA currently is undervalued (b) Both CRXA and CLTR were awfully overvalued and (c) CRXA investors were so committed to buying and selling dreams that getting closer to the actual product sales (Bexxar) detracts from the market cap.